OBIO
Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. insider trading
Insiders at Orchestra BioMed Holdings, Inc. have been buying its stock on the open market. The largest purchase in the last 30 days was Hochman David P (See Remarks · Director) buying $47.9K of OBIO, filed Sep 08, 2026. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.
- Bought on the open market
- $47.9K
- Sold
- —
- Insiders
- 1
- Latest trade
- Sep 03, 2026
From SEC filings · last 30 days
Recent OBIO insider transactions
Hochman David PSee Remarks · Director
Bought 10,000 sh at $4.79 · Sep 03, 2026
$47.9K
Filing
SEC Form 4 data, Q3 2024 to Q2 2026
OBIO insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 8 insiders traded OBIO on the open market: 25 purchases worth $2.6M and 11 sales worth $291.9K, 1 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 14 purchases ($2.2M) and 2 sales ($58.2K), by 7 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | +$158.1K5 buys | −$58.2K2 sales · 1 on a plan | |
| Q1 2026 | +$42.9K1 buy | — | |
| Q4 2025 | +$20.4K1 buy | — | |
| Q3 2025 | +$2M7 buys | — | |
| Q2 2025 | +$275.7K2 buys | −$8.2K1 sale | |
| Q1 2025 | — | — | |
| Q4 2024 | +$48K3 buys | — | |
| Q3 2024 | +$62.5K6 buys | −$225.6K8 sales |
- Largest purchase
- +$1.9M of OBIO by Perceptive Life Sciences Master Fund Ltd (10% Owner) on Aug 01, 2025.
- Largest sale
- −$58.1K of OBIO by Sherman Darren (See Remarks · Director) on Jun 01, 2026, under a 10b5-1 plan.
Open-market transactions through Jun 30, 2026most recent first
Sherman Darren10b5-1
See Remarks · Director
−$58.1K
Jun 01, 2026
15,000 sh · $3.87
Hochman David P
See Remarks · Director
+$19.2K
Jun 01, 2026
5,000 sh · $3.83
Aryeh Jason
Director
+$2.5K
May 18, 2026
665 sh · $3.75
Aryeh Jason
Director
+$35K
May 15, 2026
8,971 sh · $3.90
Hochman David P
See Remarks · Director
+$18.9K
May 15, 2026
5,000 sh · $3.77
Fain Eric S
Director
+$82.6K
May 14, 2026
20,000 sh · $4.13
Rtw Investments, LP
10% Owner
−$132
Apr 27, 2026
32 sh · $4.13
Hochman David P
See Remarks · Director
+$42.9K
Mar 13, 2026
10,000 sh · $4.29
Hochman David P
See Remarks · Director
+$20.4K
Nov 14, 2025
5,000 sh · $4.07
Aryeh Jason
Director
+$2.5K
Sep 19, 2025
1,000 sh · $2.45
Fain Eric S
Director
+$15K
Aug 25, 2025
5,760 sh · $2.61
Sherman Darren
See Remarks · Director
+$7.9K
Aug 25, 2025
3,000 sh · $2.62
Taylor Andrew Lawrence
Chief Financial Officer
+$5.1K
Aug 25, 2025
2,000 sh · $2.55
Hochman David P
See Remarks · Director
+$14.9K
Aug 21, 2025
6,000 sh · $2.49
Hochman David P
See Remarks · Director
+$55K
Aug 04, 2025
20,000 sh · $2.75
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Jun 01, 2026 | Sherman Darren10b5-1See Remarks · Director | 15,000 | $3.87 | −$58.1K |
| Jun 01, 2026 | Hochman David PSee Remarks · Director | 5,000 | $3.83 | +$19.2K |
| May 18, 2026 | Aryeh JasonDirector | 665 | $3.75 | +$2.5K |
| May 15, 2026 | Aryeh JasonDirector | 8,971 | $3.90 | +$35K |
| May 15, 2026 | Hochman David PSee Remarks · Director | 5,000 | $3.77 | +$18.9K |
| May 14, 2026 | Fain Eric SDirector | 20,000 | $4.13 | +$82.6K |
| Apr 27, 2026 | Rtw Investments, LP10% Owner | 32 | $4.13 | −$132 |
| Mar 13, 2026 | Hochman David PSee Remarks · Director | 10,000 | $4.29 | +$42.9K |
| Nov 14, 2025 | Hochman David PSee Remarks · Director | 5,000 | $4.07 | +$20.4K |
| Sep 19, 2025 | Aryeh JasonDirector | 1,000 | $2.45 | +$2.5K |
| Aug 25, 2025 | Fain Eric SDirector | 5,760 | $2.61 | +$15K |
| Aug 25, 2025 | Sherman DarrenSee Remarks · Director | 3,000 | $2.62 | +$7.9K |
| Aug 25, 2025 | Taylor Andrew LawrenceChief Financial Officer | 2,000 | $2.55 | +$5.1K |
| Aug 21, 2025 | Hochman David PSee Remarks · Director | 6,000 | $2.49 | +$14.9K |
| Aug 04, 2025 | Hochman David PSee Remarks · Director | 20,000 | $2.75 | +$55K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Don't check OBIO — let it ping you
Watch every insider filing the minute it clears the SEC
The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.
Orchestra BioMed Holdings, Inc. is outside the ~660 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.
Other companies insiders are buying now
Questions
- Are OBIO insiders buying or selling?
- Between Sep 03, 2026 and Sep 03, 2026, 1 Orchestra BioMed Holdings, Inc. insider made 1 open-market purchase worth $47.9K and no sales, a net purchase of $47.9K.
- How much OBIO stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 8 Orchestra BioMed Holdings, Inc. insiders made 25 open-market purchases worth $2.6M and 11 sales worth $291.9K. 1 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 14 purchases ($2.2M) and 2 sales ($58.2K). The largest purchase was Perceptive Life Sciences Master Fund Ltd buying $1.9M on Aug 01, 2025. The largest sale was Sherman Darren selling $58.1K on Jun 01, 2026.
- What was the largest recent OBIO insider trade?
- Hochman David P (See Remarks · Director) bought $47.9K of OBIO stock on Sep 03, 2026 at about $4.79 a share.
- When did an insider last buy OBIO shares?
- The most recent open-market purchase on file is Hochman David P (See Remarks · Director) buying $47.9K on Sep 03, 2026.
- Where does OBIO insider trading data come from?
- From the Form 4 filings Orchestra BioMed Holdings, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
The week's real signals — open-market insider buys, cluster formations and what insiders did in OBIO and across the market — in plain English, with grants and routine vesting stripped out. Free, and honest about what the data can and cannot say.